Short-course 177Lu-PSMA-617 Radioligand Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer: Time to Take the Leap?

Eur Urol. 2021 Sep;80(3):390-392. doi: 10.1016/j.eururo.2021.06.012. Epub 2021 Jun 24.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Humans
  • Leuprolide / therapeutic use
  • Lutetium / therapeutic use*
  • Male
  • Prostate-Specific Antigen / blood
  • Prostate-Specific Antigen / therapeutic use*
  • Prostatic Neoplasms* / blood
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / radiotherapy
  • Prostatic Neoplasms* / secondary
  • Radiopharmaceuticals / therapeutic use*
  • Treatment Outcome

Substances

  • 177Lu-PSMA-617
  • Antineoplastic Agents, Hormonal
  • Radiopharmaceuticals
  • Lutetium
  • Prostate-Specific Antigen
  • Leuprolide